Home › Funds › BAKER BROS. ADVISORS LP › BCYC
BAKER BROS. ADVISORS LP position in BCYC
BICYCLE THERAPEUTICS PLC · Health Care
BAKER BROS. ADVISORS LP reported holding 10,885,357 shares of BCYC (BICYCLE THERAPEUTICS PLC) in its Q2 2026 13F filing — a position valued at US$46.2M, representing 0.24% of its reported portfolio and ranking #37 among its reported holdings. BAKER BROS. ADVISORS LP has disclosed BCYC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How BAKER BROS. ADVISORS LP's BCYC position evolved
BAKER BROS. ADVISORS LP first disclosed a stake in BCYC in Q3 2023 at 843,814 shares (US$17.0M). The position peaked in Q3 2024 at 9,399,960 shares, worth US$212.7M. Across 12 filings, BAKER BROS. ADVISORS LP increased the stake 4 time(s), trimmed it 0 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 10,885,357 shares valued at US$46.2M. Notable position changes include a 112% increase in Q4 2023 (shares rose 38% over the following quarter), a 176% increase in Q1 2024 (shares fell 19% over the following quarter), a 90% increase in Q2 2024 (shares rose 12% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 843.81K | $16.95M | New |
| Q4 2023 | 1.79M | $32.37M | Add |
| Q1 2024 | 4.94M | $123.08M | Add |
| Q2 2024 | 9.40M | $190.26M | Add |
| Q3 2024 | 9.40M | $212.72M | Hold |
| Q4 2024 | 10.89M | $152.39M | Add |
| Q1 2025 | 10.89M | $92.42M | Hold |
| Q2 2025 | 10.89M | $75.65M | Hold |
| Q3 2025 | 10.89M | $84.25M | Hold |
| Q4 2025 | 10.89M | $77.07M | Hold |
| Q1 2026 | 10.89M | $50.51M | Hold |
| Q2 2026 | 10.89M | $46.15M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About BCYC and 13F data
BCYC (BICYCLE THERAPEUTICS PLC) is a Health Care company. 10 other funds we track also report a position in BCYC — the largest reported positions include FCPM III SERVICES B.V. (US$14.7M), Long Focus Capital Management, LLC (US$14.0M), GSK plc (US$6.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding BCYC
- FCPM III SERVICES B.V. 3.47M sh · $14.71M · Q2 2026
- Long Focus Capital Management, LLC 3.31M sh · $14.04M · Q2 2026
- GSK plc 1.53M sh · $6.49M · Q2 2026
More on BAKER BROS. ADVISORS LP
FAQ
How long has BAKER BROS. ADVISORS LP held BCYC?
BAKER BROS. ADVISORS LP has disclosed BCYC holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is BAKER BROS. ADVISORS LP's current position in BCYC?
As of Q2 2026, BAKER BROS. ADVISORS LP holds 10.89M shares of BCYC (BICYCLE THERAPEUTICS PLC), valued at $46.15M, representing 0.24% of its reported portfolio and ranking #37.
Has BAKER BROS. ADVISORS LP been buying or selling BCYC?
In the latest 13F filing (Q2 2026), BAKER BROS. ADVISORS LP held unchanged its position in BCYC. The position peaked in Q3 2024 at 9.40M shares.
Which other funds hold BCYC?
Other major institutional holders of BCYC include FCPM III SERVICES B.V., Long Focus Capital Management, LLC, GSK plc, among 10 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.